Business
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
Program to Highlight UGN-102 and Company’s Innovative Early-stage Pipeline Programs Company to Report Third Quarter 2021 Financial Results on November 15,
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\nProgram to Highlight UGN-102 and Company’s Innovative Early-stage Pipeline Programs\n\nCompany to Report Third Quarter 2021 Financial Results on November 15, 2021\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will host a virtual “Spotlight Event” on Wednesday, November 10, 2021 at 11:00 a.m. Eastern Time. The event will focus on UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC), and the Company’s earlier-stage clinical programs including UGN-301 and UGN-302.\n\nIn addition to presentations from UroGen’s Chairman Arie Belldegrun, M.D. and members of the Company’s senior management team, the program will include a Key Opinion Leader panel discussion on the treatment of NMIBC.\n\nPlease register for the webinar on the Company's website at www.urogen.com under the Events & Presentations section of the Investor Relations site (https://investors.urogen.com/events-and-presentations).\n\nFollowing the live audio webcast, a replay will be available on the Company's website for approximately 30 days.\n\nThird Quarter 2021 Financial Results\n\nAdditionally, the Company announced that it will report third quarter 2021 financial results on Monday, November 15, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.\n\nThe webcast will be available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for 30 days.\n\nDial-In Information\n\nLive (U.S. / Canada): (855) 765-5685\nLive (International): (615) 247-5916\nConfirmation number: 1908609\n\nAbout UroGen Pharma Ltd.\nUroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable ...